Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8609212 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNANPC1GAAKMT2A | |
| SCHEMBL11181362 | 0.87 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNANPC1GAAKMT2A | |
| SCHEMBL11189035 | 0.87 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNANPC1GAAKMT2A | |
| SCHEMBL11819805 | 0.84 | LMNA (0.64) | SMN1; SMN2LMNANPC1GAAKMT2A | |
| SCHEMBL3920974 | 0.83 | GAA (0.87) | SMN1; SMN2LMNANPC1GAAKMT2A | |
| SCHEMBL7335509 | 0.83 | ALDH1A1 (0.72) | SMN1; SMN2LMNAGAAKMT2AMEN1 | |
| SCHEMBL11179939 | 0.81 | NPC1 (0.64) | SMN1; SMN2LMNANPC1GAAKMT2A | |
| SCHEMBL10961752 | 0.81 | NPC1 (0.64) | SMN1; SMN2LMNANPC1GAAKMT2A | |
| SCHEMBL34850 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1GAAKMT2A | |
| SCHEMBL394260 | 0.81 | LMNA (0.69) | SMN1; SMN2LMNANPC1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-7427612-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1663232-B1 | 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| EP-1663232-A1 | 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | disclosed |
| WO-2005023260-A1 | 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| EP-0023964-B1 | PHENYLIMINOTHIAZOLINE DERIVATIVES, THEIR PREPARATION AND INTERMEDIATES THEREFOR, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR PRODUCTION | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-16 | — | — | EP | disclosed |
| EP-0023964-A1 | Phenyliminothiazoline derivatives, their preparation and intermediates therefor, pharmaceutical preparations containing them and their production | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-02-18 | — | — | EP | disclosed |
| US-3954994-A | Intermediates for preparing hipolipemic agents and method of lowering the blood lipid level in mammals with said agents | PFIZER INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | SMN1; SMN2 1564/4885LMNA 1202/4885NPC1 248/4885 |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | SMN1; SMN2 227/4885LMNA 4692/4885NPC1 780/4885 |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | OPRL1, ACHE, PNMT | SMN1; SMN2 227/4885LMNA 4692/4885NPC1 780/4885 |
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | SMN1; SMN2 2089/4885LMNA 4722/4885NPC1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.